Longevity Protocols

The only commercially available 5-day dietary program with Phase II clinical trial data showing measurable biological age reduction. Developed over 20 years by Dr. Valter Longo at USC and IFOM Milan — the world's most-cited fasting longevity researcher. The mechanism is precise: 800–1,100 calories of plant-based, low-protein, low-carb food designed to keep cells in a fasting state while preventing starvation signaling. This triggers autophagy (cellular cleanup), stem cell activation, and regenerative pathways that normal eating suppresses.

Key published evidence: Brandhorst et al. (Cell Metabolism, 2015): first human RCT showing multi-system rejuvenation in healthy subjects. Fitzgerald et al. (Aging, 2020): 3-cycle ProLon reduced TruDiagnostic biological age by average 2.5 years. Longo et al. (Nature Medicine, 2022): Phase II clinical trial showing reduced metabolic disease risk factors. IGF-1 reduced 11–15% (cancer/aging driver). CRP reduced (systemic inflammation marker). Lean muscle mass preserved — caloric restriction alone cannot achieve this. The ProLon protocol is the only FMD with FDA-authorized disease risk reduction claim.

A 9-compound senolytic formula administered as a 2-day-on, rest-of-month-off protocol — mirroring how senolytics are used in Mayo Clinic and Scripps Institute clinical research. Key ingredients: quercetin phytosome (superior bioavailability vs. standard quercetin), fisetin (most potent senolytic of 10 flavonoids tested, EBioMedicine 2018), piperlongumine, apigenin, and luteolin. The clinical reference point: Mayo Clinic Lancet 2025 dasatinib + quercetin trials showed −23% working memory decline, −31% mobility loss, −40% senescent cell markers. Qualia's quercetin phytosome delivers equivalent or superior quercetin bioavailability without requiring a chemotherapy drug co-administration.

Protocol: 6 capsules daily on 2 consecutive days each month (12 capsules total per cycle). Take with food and extra water. Wait ~4 weeks before repeating. Can be combined with ProLon on Q1/Q3 cycles for synergistic autophagy + senolytic clearance.

The most comprehensive NAD+ precursor formula available — the only product combining all three clinically validated NAD+ pathways in a single formula. Contains patented Niagen® NR (ChromaDex partnership — 5+ human RCTs, USP Verified), NMN (Yoshino 2021 Cell Metabolism pathway), and niacin (the original NAD+ precursor with the most decades of safety data). Co-factors included: TMG (methyl donor to prevent SAMe depletion from NAD+ synthesis), riboflavin, and L-tryptophan. Clinically demonstrated 67% NAD+ blood elevation in double-blind placebo-controlled trial — the highest documented single-formula NAD+ increase in peer-reviewed literature.